Form 4: Apyx Medical Corp CEO Charles D. Goodwin II Granted Stock Options

Charles D. Goodwin II, CEO of Apyx Medical Corp, reports the acquisition of stock options.

Summary

• Charles D. Goodwin II, the CEO of Apyx Medical Corp, filed a Form 4 with the SEC.
• The report details the granting of stock options.
• On May 15, 2025, Goodwin was granted options to buy 193,000 shares of Apyx Medical Corp common stock at an exercise price of $1.48 per share.
• The options vest ratably over 36 months and become fully vested on the third anniversary of the grant date, expiring on May 15, 2035.
• Following the transaction, Goodwin directly owns options for 193,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the medical device industry to incentivize and retain key executives.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Apyx Medical Corp, Charles D. Goodwin II, CEO, beneficial ownership, securities